Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Suppression of p24 antigen in sera from HIV-infected individuals with low-dose alpha-interferon and zidovudine: a pilot study.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  1. Prevalence and risk factors of prolonged QT interval and electrocardiographic abnormalities in persons living with HIV

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiators

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Primary resistance to integrase strand-transfer inhibitors in Europe

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk of HIV or second syphilis infection in Danish men with newly acquired syphilis in the period 2000-2010

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
On the basis of the observations that HIV antigenaemia indicates a high risk of progression to AIDS and that zidovudine and alpha-interferon act synergistically against HIV replication in vitro, we performed a pilot trial including 12 HIV-infected asymptomatic patients with detectable p24 antigen in serum. The patients received low-dose lymphoblastoid alpha-interferon alone for 4 weeks followed by a combination of interferon and low-dose zidovudine for a further 16 weeks. The median p24 antigen level decreased significantly (P less than 0.01), the decrease being most pronounced at week 5. Decreases in haemoglobin and neutrophil counts were observed. Four patients required reduction of the zidovudine dose and three patients were transfused. In conclusion, the drug combination was capable of reducing the serum level of HIV p24 antigen and it was tolerated by the patients. Further studies are required to evaluate the clinical implications of these observations.
Bidragets oversatte titelSuppression of p24 antigen in sera from HIV-infected individuals with low-dose alpha-interferon and zidovudine: a pilot study.
OriginalsprogEngelsk
TidsskriftAIDS (London, England)
Vol/bind3
Udgave nummer2
Sider (fra-til)97-100
Antal sider4
ISSN0269-9370
StatusUdgivet - 1989

ID: 32517466